Press release
ER+/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects
Key Takeaways from the ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report
* DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment.
* The leading ER+/ HER2 -ve Breast Cancer Companies such as BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
* Promising ER+/ HER2 -ve Breast Cancer Therapies such as G1T48, Palbociclib, and others.
Request a sample and discover the recent advances in ER+/ HER2 -ve Breast Cancer @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70-80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen. HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
ER+/ HER2 -ve Breast Cancer Emerging Drugs Profile
* AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
* BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
Learn more about ER+/ HER2 -ve Breast Cancer in clinical trials @ ER+/ HER2 -ve Breast Cancer Drugs [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Therapeutics Assessment
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The ER+/ HER2 -ve Breast Cancer companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report covers around 50+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage products (Phase I/II and Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Discover more about ER+/ HER2 -ve Breast Cancer in development @ ER+/ HER2 -ve Breast Cancer Clinical Trials [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Companies
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravaginal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
To know more about ER+/ HER2 -ve Breast Cancer, visit @ ER+/ HER2 -ve Breast Cancer Segmentation [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report
* Coverage- Global
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* ER+/ HER2 -ve Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
* ER+/ HER2 -ve Breast Cancer Therapies- G1T48, Palbociclib, and others.
For further information on the ER+/ HER2 -ve Breast Cancer Pipeline Therapeutics, reach out @ ER+/ HER2 -ve Breast Cancer Products Development [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* ER+/ HER2-VE Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* AZD9833: Astrazeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BGB-290: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* OP-1250: Olema Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* ER+/ HER2-VE Breast Cancer Key Companies
* ER+/ HER2-VE Breast Cancer Key Products
* ER+/ HER2-VE Breast Cancer- Unmet Needs
* ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
* ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
* ER+/ HER2-VE Breast Cancer Analyst Views
* ER+/ HER2-VE Breast Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ER+/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects here
News-ID: 3526032 • Views: …
More Releases from ABNewswire
Winter Olympics Pass Launches as the Definitive Digital Companion for the 2026 M …
NEW YORK, NY - As the world turns its gaze toward the snowy peaks of Italy for the highly anticipated Milano Cortina 2026 Games, sports enthusiasts face the perennial challenge of tracking the sprawling, multi-disciplinary event. Today marks the official launch of a comprehensive digital solution designed to streamline this experience: the Winter Olympics Pass [https://winterolympicspass.com/]. This new platform serves as a centralized hub, delivering real-time schedules, in-depth results, and…
Monmouth County Trust Attorney Christine Matus Explains What a Pooled Special Ne …
TOMS RIVER, NJ - Individuals with disabilities can protect assets without jeopardizing Medicaid or Supplemental Security Income eligibility through pooled special needs trusts managed by nonprofit organizations. Monmouth County trust attorney Christine Matus of The Matus Law Group (https://matuslaw.com/what-is-a-pooled-special-needs-trust-in-new-jersey/) is helping New Jersey families understand how pooled trusts work, who qualifies, and the benefits and limitations of this estate planning tool under federal and state law.
According to Monmouth County trust…
Annual Review | Slkor's Top 20 Chip News of 2025
Explore Slkor Semiconductor's 2025 journey through 20 key events, including market expansion, brand growth, product innovation, overseas breakthroughs, and team development. A comprehensive look at a year of progress and partnership.
Time never stands still, and the seasons flow on. Standing at the new starting point of 2026 and looking back, we sincerely thank every customer and partner for your companionship and trust throughout 2025. This year at Slkor was enriched…
Chicago Estate Planning Attorney Mary Liberty of Illinois Estate Law Outlines Tr …
CHICAGO, IL - Proper trust funding is essential to making any estate plan work, according to Chicago Estate Planning Attorney Mary Liberty of Illinois Estate Law (https://www.illinoisestatelaw.com/trust-funding-check-list/). While many individuals take the important step of establishing a trust to protect their assets and avoid probate, too often they stop short of completing the process by failing to fund the trust. This oversight can derail even the most carefully drafted plans.
Mary…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
